Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals.

According to the terms of the agreement, Madrigal will pay Arrowhead a $25 million upfront payment, with the possibility of up to an additional $975 million in future payments based on research and development milestones. This collaboration involves Arrowhead's proprietary technology in the treatment of non-alcoholic steatohepatitis (NASH). Both parties will jointly advance the development of related therapies, and Arrowhead is expected to receive total revenue of up to $1 billion through the achievement of specific development, registration, and commercial milestones. This collaboration highlights the recognition of Arrowhead's technological strength in the field of RNA interference therapies within the industry.